期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

LC-MS法检测与分析罗氟司特中的杂质 被引量：3

Determination and analysis of the impurities in Roflumilast by LC-MS
原文传递
导出
摘要 目的用LC-MS法测定罗氟司特中的有关物质。方法采用C18色谱柱,电喷雾离子源,正离子检测方式。结果在罗氟司特原料药中检测到2个主要杂质。结论成功地鉴定了罗氟司特中两个杂质的结构。 OBJECTIVE An LC - MS method was established for the determination of the major related substance in Roflumilast. METHODS A C18 column was used and ESI was applied and operated in positive ion mode. RESULTS Two impurities were detected in Roflumilast. CONCLUSION The structures of two impurities in Roflumilast have been identified successfully.
作者 冷柏榕 严相平
机构地区 南京工业大学 江苏省药物研究所
出处 《华西药学杂志》 CAS CSCD 北大核心 2014年第4期438-439,共2页 West China Journal of Pharmaceutical Sciences
关键词 罗氟司特 有关物质 液相色谱-串联质谱 Roflumilast Related substance LC - MS
分类号 R917 [医药卫生—药物分析学]
  • 相关文献

参考文献1

二级参考文献21

  • 1World Health Organization. World health statistics 2008[R]. Geneva,Switzerland:World Health Organization,2008.
  • 2Barnes PJ. Future treatments for chronic obstructive pulmonary disease and its comorbidities[J]. Proc Am Thorac Soc,2008,5(8) :857-864.
  • 3Giembycz MA,Field SK. R0flumilast:first phosphodiesterase 4 inhibitor approved for treatment of COPD[J]. Drug Des Devel Ther,2010,21 (4) : 147-158.
  • 4Global strategy ~or the diagnosis, management,and prevention of chronic obstructive pulmonary disease revised 2011. [EB/ OL](2012-12) [2012-06-10]. http://www.google. com. hk/ url. htm.
  • 5Hatzelmann A, Morcillo E J, Lungarella G, et al. The preclinical pharmacology of roflumilast-a selective,oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease[J]. Pulm Pharmacol Ther, 2010,23(4) : 235-256.
  • 6Rabe KF, Baleman ED, O' Donnell D, et al. Roflumilast-an oral antl-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial[J]. Lancet, 2005, 366 (9485) :563-571.
  • 7Calverley PM, Sanchez Toril F, Mclvor A, et al. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med,2007,176 (2):154-161.
  • 8Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. Ratio-Study. (BY217/ M2-112) [EB/OL]. ( 2012-05-04 ) [2012-06-10]. http:// www. clinicaltrials.gov/ct2/show/NCT00430729, htm.
  • 9Rennard SI, Calverley PM, Goehring UM, et al. Reduction of exacerbations by the PDE4 inhibitor roflumilast-the importance of defining different subsets of patients with COPD[J]. Respir Res,2011,27(12):18.
  • 10OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111) [EB/OL]. (2012 05-04) E2012-06-103. http://www.clinicaltrials.gov/ct2/show/NCT00076089. htm.

共引文献9

同被引文献9

引证文献3

华西药学杂志
2014年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部